STVN

Stevanato Group Spa

19.17

Jul 17 • 03:59PM ET -0.93 (-4.63%)

19.17

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Medical Instruments & Supplies Italy Mid NYSE

Peers: ICUI TFX AVTR BDX BAX RMD MASI EW BSX MDT

| Held by: IBB KOMP NBSM AIMS BCSM SMLV BCGD SCAP TMED FESC

Index	-
Market Cap	5.23B
Enterprise Value	5.62B
Income	164.01M
Sales	1.40B
Book/sh	6.46
Cash/sh	0.47
Dividend Est.	0.05 (0.28%)
Dividend TTM	0.06 (0.33%)
Dividend Ex-Date	Jun 11, 2026
Dividend Gr. 3/5Y	0.00% -
Payout	10.76%
Employees	-
IPO	Jul 16, 2021

P/E	31.91
Forward P/E	23.37
PEG	1.39
P/S	3.75
P/B	2.97
P/C	40.67
P/FCF	903.88
EV/EBITDA	16.89
EV/Sales	4.03
Quick Ratio	1.11
Current Ratio	1.63
Debt/Eq	0.29
LT Debt/Eq	0.21
Option/Short	Yes / Yes

EPS (ttm)	0.60
EPS next Y	0.82
EPS next Q	0.15
EPS this Y	11.58%
EPS next Y	18.95%
EPS next 5Y	16.78%
EPS past 3/5Y	0.64% 11.33%
Sales past 3/5Y	9.00% 12.15%
EPS Y/Y TTM	21.77%
Sales Y/Y TTM	15.54%
EPS Q/Q	17.40%
Sales Q/Q	18.52%
Earnings	May 07 BMO
EPS/Sales Surpr.	6.16% 2.37%

Insider Own	81.79%
Insider Trans	-0.00%
Inst Own	17.51%
Inst Trans	-2.23%
ROA	5.98%
ROE	9.96%
ROIC	7.68%
Gross Margin	28.10%
Oper. Margin	16.26%
Profit Margin	11.76%
SMA20	2.82%
SMA50	5.14%
SMA200	0.80%
Trades

Shs Outstand	49.71M
Shs Float	49.71M
Short Float	1.90%
Short Ratio	2.34
Short Interest	0.95M
52W High	28.00 -31.54%
52W Low	12.89 48.72%
Volatility	4.88% 4.82%
ATR (14)	0.89
RSI (14)	54.13
Beta	0.77
Rel Volume	0.66
Avg Volume	404.89K
Volume	268,828

Perf Week	-2.14%
Perf Month	16.11%
Perf Quarter	27.54%
Perf Half Y	-6.30%
Perf YTD	-4.72%
Perf Year	-24.79%
Perf 3Y	-39.51%
Perf 5Y	-2.54%
Perf 10Y	-
Recom	1.33
Target Price	24.09
Prev Close	20.10
Price	19.17
Change	-4.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-26	Initiated	TD Cowen	Buy	$25
Jun-02-26	Resumed	Wolfe Research	Outperform	$21
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight	$24
Dec-13-24	Initiated	Wolfe Research	Outperform	$28
Dec-03-24	Resumed	Morgan Stanley	Equal-Weight	$23
Apr-22-24	Initiated	Exane BNP Paribas	Outperform
Nov-01-23	Downgrade	Jefferies	Buy → Hold	$39 → $29
Sep-26-23	Initiated	Stephens	Overweight	$33
Sep-19-23	Initiated	CJS Securities	Market Outperform
Aug-24-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$34
Aug-10-21	Initiated	Wells Fargo	Overweight	$24
Aug-10-21	Initiated	Morgan Stanley	Overweight	$26
Aug-10-21	Initiated	KeyBanc Capital Markets	Overweight	$27
Aug-10-21	Initiated	Jefferies	Buy	$25
Aug-10-21	Initiated	Citigroup	Buy	$27
Aug-10-21	Initiated	BofA Securities	Buy	$26

Show Previous Ratings

Jun-08-26 06:30AM	Stevanato Group Introduces Deora, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management (Business Wire)
Jun-03-26 05:45PM	Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting (Business Wire)
May-08-26 08:30AM	Stevanato Group S.p.A. Q1 2026 Earnings Call Summary (Moby)
May-07-26 06:41AM	Stevanato: Q1 Earnings Snapshot (Associated Press) -5.11%
06:30AM	Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026 (Business Wire)
05:45PM	Loading…
May-04-26 05:45PM	Stevanato Group to Participate in Three Upcoming Investor Conferences (Business Wire)
Apr-23-26 04:05PM	Stevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Mar-12-26 04:45PM	Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum (Business Wire)
Mar-04-26 04:01PM	Stevanato Group SpA (STVN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +18.81% -9.09%
01:47PM	Stevanato Group Q4 Earnings Call Highlights (MarketBeat)
12:35PM	Stevanato Group S.p.A. Q4 2025 Earnings Call Summary (Moby)
07:45AM	Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:48AM	Stevanato: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins (Business Wire)
Feb-26-26 09:55AM	Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:35AM	Loading…
Feb-19-26 07:35AM	Here's What Hurt Stevanato Group SpA (STVN) in Q4 (Insider Monkey)
06:30AM	Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026 (Business Wire)
Jan-26-26 11:40AM	STVN or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-23-26 04:34PM	Stocks Finish Mostly Higher Despite a Plunge in Intel (Barchart) -9.86%
Jan-20-26 09:05AM	Stevanato (STVN) Declined Due to Anticipation of Soft Quarter Ahead (Insider Monkey)
Jan-16-26 05:05AM	Datwyler, LTS Device Technologies, and Stevanato Group Collaborate to Expand Self-Delivery Options for Large-Volume Drugs (PR Newswire) -5.95%
Dec-24-25 08:34AM	Are Options Traders Betting on a Big Move in Stevanato Group Stock? (Zacks)
Dec-19-25 11:40AM	SDZNY vs. STVN: Which Stock Is the Better Value Option? (Zacks)
Dec-03-25 11:40AM	SDZNY vs. STVN: Which Stock Should Value Investors Buy Now? (Zacks) +5.70%
Nov-06-25 07:45AM	Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
06:38AM	Stevanato: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Stevanato Group Reports Revenue of 303.2 Million for the Third Quarter of 2025 (Business Wire)
Oct-31-25 12:09PM	SDZNY vs. STVN: Which Stock Is the Better Value Option? (Zacks)
07:30AM	Stevanato Group to Participate in Upcoming Investor Conferences (Business Wire)
Oct-22-25 06:30AM	Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
06:30AM	Loading…
Oct-21-25 06:30AM	Stevanato Group Expands Drug Delivery Systems Capacity to Strengthen Global Integrated Offerings (Business Wire)
Oct-10-25 11:40AM	GRFS vs. STVN: Which Stock Should Value Investors Buy Now? (Zacks)
Oct-07-25 06:04AM	NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Sep-15-25 11:40AM	USNA vs. STVN: Which Stock Is the Better Value Option? (Zacks)
Sep-12-25 08:16AM	Stevanato Group SpA (STVN) Share Gained 20% as Results Exceeded Expectations (Insider Monkey)
Sep-11-25 12:00PM	Stevanato (STVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-02-25 05:59PM	Stevanato Group to Participate in Upcoming Investor Conferences (Business Wire)
Aug-28-25 11:40AM	USNA or STVN: Which Is the Better Value Stock Right Now? (Zacks)
Aug-25-25 08:30AM	Here's Why Artisan Small Cap Fund Increased its Holdings in Stevanato Group S.p.A. (STVN) (Insider Monkey)
Aug-12-25 11:40AM	USNA vs. STVN: Which Stock Is the Better Value Option? (Zacks)
Aug-05-25 07:40AM	Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates (Zacks) -9.73%
06:38AM	Stevanato: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	Stevanato Group Reports Revenue of 280.0 Million for the Second Quarter of 2025 (Business Wire)
Jul-29-25 10:00AM	Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-25-25 11:40AM	MKKGY or STVN: Which Is the Better Value Stock Right Now? (Zacks) -5.15%
10:06AM	Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-23-25 01:18PM	Will Escalating Medical Costs Dampen Centene's Q2 Earnings? (Zacks)
06:30AM	Stevanato Group Secures 200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S. (Business Wire)
Jul-22-25 04:30PM	Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025 (Business Wire)
Jul-09-25 11:40AM	CPRX or STVN: Which Is the Better Value Stock Right Now? (Zacks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
11:40AM	FMS or RXST: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	GBOOY vs. BAM: Which Stock Should Value Investors Buy Now? (Zacks)
11:40AM	FLEX vs. GRMN: Which Stock Is the Better Value Option? (Zacks)
11:40AM	GLDD vs. DY: Which Stock Is the Better Value Option? (Zacks)
11:40AM	DNBBY or CMWAY: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CCU or SAM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	TTEC or MLNK: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	STRT or RACE: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	STNE vs. FFIV: Which Stock Is the Better Value Option? (Zacks)
11:40AM	GO or KMB: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CRRFY or WMT: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	ASAIY vs. K: Which Stock Is the Better Value Option? (Zacks)
11:40AM	USNA vs. STVN: Which Stock Is the Better Value Option? (Zacks)
Jun-02-25 11:40AM	GRFS vs. STVN: Which Stock Is the Better Value Option? (Zacks)
May-30-25 01:07AM	Stevanato Group S.p.A. (STVN): A Bull Case Theory (Insider Monkey)
May-09-25 04:03PM	Stevanato Group to Participate in Upcoming Investor Conferences (Business Wire) +6.76%
03:20AM	Stevanato Group SpA (STVN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-08-25 07:50AM	Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates (Zacks)
06:46AM	Stevanato: Q1 Earnings Snapshot (Associated Press Finance)
06:37AM	Stevanato Group Reports Revenue of 256.6 Million for the First Quarter of 2025 (Business Wire)
May-07-25 09:41AM	Stevanato Group SpA (STVN) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-06-25 11:40AM	SDZNY vs. STVN: Which Stock Should Value Investors Buy Now? (Zacks)
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-24-25 05:15PM	Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Mar-11-25 04:30PM	Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum (Business Wire) -6.46%
Mar-07-25 02:09AM	Stevanato Group SpA (STVN) Q4 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
01:52AM	Q4 2024 Stevanato Group SpA Earnings Call (Thomson Reuters StreetEvents)
Mar-06-25 07:45AM	Stevanato Group (STVN) Meets Q4 Earnings Estimates (Zacks) +8.60%
06:48AM	Stevanato: Q4 Earnings Snapshot (Associated Press Finance)
06:31AM	Stevanato Group Reports Record Revenue of 1,104 Million for Fiscal Year 2024 (Business Wire)
Mar-05-25 07:05AM	Earnings To Watch: Stevanato Group SpA (STVN) Reports Q4 2024 Result (GuruFocus.com)
Feb-24-25 04:02PM	Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-23-25 01:35PM	Stevanato Group S.p.A. (STVN): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-13-25 12:16AM	Is Stevanato Group S.p.A. (STVN) the Best Italian Stock to Buy in 2025? (Insider Monkey) -5.08%
Jan-07-25 04:30PM	Stevanato Group to Present at Upcoming Investor Conference (Business Wire)
Dec-14-24 06:45AM	Wolfe starts Stevanato with Outperform on return to growth (TipRanks)
Dec-04-24 07:55AM	Stevanato Group assumed with an Equal Weight at Morgan Stanley (TipRanks)
Nov-11-24 06:32AM	Stevanato Group to Present at Upcoming Investor Conferences (Business Wire)
Nov-06-24 02:13AM	Stevanato Group SpA (STVN) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Nov-05-24 07:45AM	Stevanato Group (STVN) Q3 Earnings Match Estimates (Zacks) +16.10%
06:43AM	Stevanato: Q3 Earnings Snapshot (Associated Press Finance)
06:31AM	Stevanato Group Reports Financial Results for the Third Quarter of 2024 (Business Wire)
Nov-04-24 07:03AM	Stevanato Group SpA (STVN) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Oct-22-24 04:30PM	Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024 (Business Wire)
10:01AM	Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-08-24 07:25AM	Nipro debuts D2F glass vials with Stevanatos EZ-fill tech (Packaging Gateway)
Oct-01-24 06:30AM	Stevanato Group Will Introduce Its Large-Volume Vertiva 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan (Business Wire)
Sep-30-24 11:31AM	Is Stevanato Group S.p.A. (STVN) the Top Italian Stock for Biopharma Investors? (Insider Monkey) -6.24%
Sep-27-24 10:48AM	Heres Why ClearBridge SMID Cap Growth Strategy Exited Stevanato (STVN) (Insider Monkey)

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

CEO & Executive ChairmanMr. Franco Stevanato

Chief Financial OfficerMr. Marco Dal Lago

Chief Communications & Investor Relations OfficerMs. Lisa Miles

Chief Human Resources OfficerMs. Carla Costa

Chief Business OfficerMr. Mauro Stocchi

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Balachandran Madhavan	Director	Jun 15 '26	Sale	17.09	1,493	25,515	69,458	Jun 26 06:18 AM
Dal Lago Marco	Chief Financial Officer	Jun 12 '26	Option Exercise	0.00	7,997	0	85,353	Jun 26 06:16 AM
MOREL DONALD E JR	Director	Jun 15 '26	Sale	17.09	1,493	25,515	37,424	Jun 26 06:12 AM
Stocchi Mauro	See Remarks	Jun 09 '26	Option Exercise	0.00	6,586	0	413,629	Jun 26 06:07 AM
Flynn Karen	Director	Jun 15 '26	Sale	17.09	1,493	25,515	5,757	Jun 26 06:05 AM
FEDERICI WILLIAM J	Director	Jun 15 '26	Sale	17.09	1,493	25,515	26,991	Jun 26 06:04 AM

Open in Screener

QURE

uniQure NV

40.25

Jul 17 • 03:59PM ET +0.89 (2.26%)

40.90

Aftermarket • 07:07PM ET +0.65 (1.61%)

Healthcare Biotechnology Netherlands Mid NASD

Peers: BEAM NTLA CRSP EDIT VIR BMRN RYTM IONS ALNY INCY

| Held by: XBI VXF IBB SCHA JGRO VHT FYC ITOT KOMP LABU

Index	-
Market Cap	2.74B
Enterprise Value	2.70B
Income	-208.87M
Sales	18.09M
Book/sh	2.37
Cash/sh	8.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	221
IPO	Feb 05, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	151.33
P/B	16.99
P/C	4.67
P/FCF	-
EV/EBITDA	-
EV/Sales	149.07
Quick Ratio	10.40
Current Ratio	10.40
Debt/Eq	3.65
LT Debt/Eq	3.63
Option/Short	Yes / Yes

EPS (ttm)	-3.51
EPS next Y	-3.00
EPS next Q	-0.83
EPS this Y	-6.38%
EPS next Y	18.61%
EPS next 5Y	24.98%
EPS past 3/5Y	-8.45% -4.24%
Sales past 3/5Y	-46.73% -15.57%
EPS Y/Y TTM	19.99%
Sales Y/Y TTM	-10.44%
EPS Q/Q	-3.85%
Sales Q/Q	127.31%
Earnings	May 05 BMO
EPS/Sales Surpr.	1.71% -31.56%

Insider Own	9.76%
Insider Trans	-7.52%
Inst Own	83.28%
Inst Trans	-3.79%
ROA	-30.18%
ROE	-228.24%
ROIC	-30.18%
Gross Margin	17.67%
Oper. Margin	-1082.08%
Profit Margin	-1154.42%
SMA20	-8.75%
SMA50	18.28%
SMA200	36.68%
Trades

Shs Outstand	63.03M
Shs Float	61.37M
Short Float	18.73%
Short Ratio	5.29
Short Interest	11.49M
52W High	71.50 -43.71%
52W Low	8.73 361.05%
Volatility	5.20% 7.15%
ATR (14)	2.83
RSI (14)	51.96
Beta	0.93
Rel Volume	0.44
Avg Volume	2.17M
Volume	958,200

Perf Week	-5.58%
Perf Month	49.13%
Perf Quarter	139.44%
Perf Half Y	80.09%
Perf YTD	68.20%
Perf Year	164.80%
Perf 3Y	277.93%
Perf 5Y	49.96%
Perf 10Y	437.38%
Recom	1.47
Target Price	64.83
Prev Close	39.36
Price	40.25
Change	2.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-18-26	Upgrade	Barclays	Equal Weight → Overweight	$65
Jun-17-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$61
Mar-11-26	Upgrade	Mizuho	Neutral → Outperform	$35
Mar-09-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$60
Mar-09-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$35
Mar-03-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$15
Mar-03-26	Downgrade	Mizuho	Outperform → Neutral	$12
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11
Mar-02-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$9
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-28-26	Initiated	Barclays	Equal Weight	$31
Nov-04-25	Downgrade	William Blair	Outperform → Mkt Perform
Aug-14-25	Upgrade	Mizuho	Neutral → Outperform	$30
Apr-01-25	Resumed	Chardan Capital Markets	Buy	$38
Dec-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-10-24	Resumed	Raymond James	Outperform	$20
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8
Dec-19-23	Downgrade	Mizuho	Buy → Neutral	$52 → $10
Mar-17-22	Upgrade	UBS	Neutral → Buy	$40
Jun-15-21	Initiated	BTIG Research	Buy	$46

Show Previous Ratings

Jul-08-26 10:15AM	3 Biotech Stocks to Watch Before Wall Street Catches On (InvestorPlace) +5.02%
Jun-29-26 07:53PM	XBI Ignored The Market's Downturn (Trefis)
Jun-25-26 04:10PM	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-23-26 09:13PM	uniQure Announces Pricing of Upsized $225 Million Public Offering (GlobeNewswire) +10.48%
Jun-22-26 04:01PM	uniQure Announces $150 Million Proposed Public Offering (GlobeNewswire)
08:24AM	Loading…
Jun-19-26 08:24AM	QURE Was Just the Beginning: 5 Biotech Catalysts Im Watching Now (InvestorPlace)
07:05AM	uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (GlobeNewswire)
Jun-18-26 10:57AM	UniQure to seek approval of Huntingtons gene therapy after FDA U-turn (Pharmaceutical Technology)
09:35AM	SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Jun-17-26 04:48PM	?? Under the Radar: uniQure Shares Surge After FDA's Reversal on Gene Therapy (The Wall Street Journal) +78.44%
10:10AM	This Biotech Stock Is Surging 66% on Surprise Good News From FDA (Barrons.com)
09:08AM	QURE Stock Surges Over 70% After FDA Softens Stance On Huntingtons Disease Gene Therapy (Stocktwits)
08:56AM	ClearPoint Neuro Shares Jump as FDA Progress for UniQure Therapy Highlights Platform Value (InvestorsHub)
08:55AM	uniQure Positioned for Gains After FDA Supports Accelerated Approval Path for AMT-130 (InvestorsHub)
07:05AM	uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease (GlobeNewswire)
05:30AM	Loading…
May-20-26 05:30AM	Biotech Investors Are Tuning Out the MAHA Chaos (The Wall Street Journal)
May-06-26 06:48PM	Oncolytics Biotech Reports Data in Colorectal Cancer Study (IPO-Edge.com) +7.84% +5.83%
May-05-26 07:21AM	UniQure: Q1 Earnings Snapshot (Associated Press)
07:05AM	uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates (GlobeNewswire)
Apr-30-26 07:05AM	uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease (GlobeNewswire) +19.25%
Apr-28-26 07:05AM	uniQure to Announce First Quarter 2026 Financial Results (GlobeNewswire)
Mar-20-26 03:23AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire) +5.44%
Mar-10-26 08:17AM	uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? (Benzinga)
Mar-09-26 04:37PM	This biotech's stock soared after a 'polarizing' FDA official is stepping down (MarketWatch) +26.07%
01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
11:17AM	uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts (24/7 Wall St.)
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com)
07:01AM	Why Is uniQure Stock Skyrocketing Monday? (Benzinga)
05:28AM	Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike-Hims & Hers, Ovintiv, Uniqure In Focus (Benzinga)
07:13PM	Loading…
Mar-06-26 07:13PM	FDA Vaccine Chief Vinay Prasad Set to Leave Post Next Month (Bloomberg) +33.99%
09:57AM	QURE Stock Crashes 32% in a Week: Here's What You Should Know (Zacks)
Mar-05-26 06:01PM	Federal Health Officials Attack Rare-Disease Drug, Say Company Lied (The Wall Street Journal) +17.81%
12:11PM	FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial (Benzinga)
Mar-04-26 09:58AM	What's Going On With uniQure Stock Wednesday? (Benzinga)
09:35AM	uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-26 11:38AM	uniQure downgraded after FDA backs sham-controlled trial for Huntingtons therapy (Investing.com) -14.00%
09:33AM	MongoDB downgraded, Block upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More (24/7 Wall St.)
Mar-02-26 04:37PM	Stocks Recover as Iran War Pushes Energy and Defense Stocks Higher (Barchart) -32.82%
04:28PM	Uniqure Plummets By A Third After Realizing 'The Worst Case Scenario' For Its Gene Therapy (Investor's Business Daily)
02:01PM	uniQure NV (QURE) Q4 2025 Earnings Call Highlights: Breakthroughs and Challenges in Gene Therapy (GuruFocus.com)
12:57PM	FDA tells uniQure to conduct another study of Huntingtons gene therapy (Clinical Trials Arena)
12:33PM	uniQure N.V. Q4 2025 Earnings Call Summary (Moby)
11:37AM	UniQure Stock Drops 36% After Earnings. Bad News From the FDA Gets Even Worse. (Barrons.com)
11:19AM	Markets Rebound After Initial Selloff Triggered by Middle East Tensions (Barchart)
10:37AM	uniQure Q4 Earnings Call Highlights (MarketBeat)
08:58AM	Uniqure Plummets More Than 40% On Another Twist In Its Gene Therapy Saga (Investor's Business Daily)
08:51AM	uniQure Stock Plunges 40% After FDA Shocker (Benzinga)
08:20AM	uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	UniQure: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces 2025 Financial Results and Provides Recent Company Updates (GlobeNewswire)
07:00AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Feb-28-26 02:21AM	Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating (Insider Monkey)
Feb-27-26 12:49AM	QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? (New feeds test provider finance) -8.68%
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily) -31.18%
09:55AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-23-26 07:05AM	uniQure to Announce 2025 Financial Results (GlobeNewswire)
Feb-18-26 09:00AM	uniQure N.V. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights - QURE (PR Newswire) +7.72%
Feb-14-26 01:28AM	UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity (Insider Monkey)
Feb-13-26 01:11AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire) -8.36%
Feb-12-26 08:00AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights QURE (Business Wire) -7.22%
Feb-06-26 01:58PM	Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch (Benzinga)
07:05AM	uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Feb-02-26 09:35AM	uniQure (QURE) Navigates Gene Therapy Development as Investors Weigh Long-Term Potential (Insider Monkey) +8.71%
Jan-20-26 09:01AM	Here's Why uniQure (QURE) Fell in Q3 (Insider Monkey)
Jan-12-26 10:11AM	Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? (Insider Monkey) -9.00%
Jan-09-26 01:14PM	uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT-130 Approval Pathway (Benzinga) +9.37%
07:05AM	uniQure Announces Type A Meeting Scheduled with FDA (GlobeNewswire)
Dec-21-25 09:56AM	What Do Analysts Think About UniQure (QURE)? (Insider Monkey)
Dec-15-25 11:11PM	UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch (Insider Monkey) +7.15%
Dec-04-25 12:18PM	uniQure N.V. (QURE): A Bear Case Theory (Insider Monkey) -10.75%
10:02AM	UniQure Plummets, Again, As FDA Indicates It Will Reject Huntington's Gene Therapy (Investor's Business Daily)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Nov-25-25 08:39AM	William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty (Insider Monkey)
Nov-19-25 08:16AM	Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 (Insider Monkey) -5.92%
Nov-17-25 12:15PM	Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA (Insider Monkey)
Nov-12-25 07:00AM	uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences (Insider Monkey)
Nov-10-25 04:01PM	uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges (GuruFocus.com) -5.90% +17.93%
08:15AM	uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:14AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:05AM	uniQure to Announce Third Quarter 2025 Financial Results (GlobeNewswire) +5.56%
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily) -14.39%
Nov-04-25 01:36PM	FDA halts uniQures plans for Huntingtons disease gene therapy (Pharmaceutical Technology) -11.23%
Nov-03-25 04:29PM	These Stocks Moved the Most Today: Kenvue, Kimberly-Clark, Amazon, uniQure, Palantir, Idexx, Cipher Mining, and More (Barrons.com) -49.34%
04:27PM	UniQure Plummets 49% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy (Investor's Business Daily)
11:15AM	uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results (Insider Monkey)
08:33AM	UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. (Barrons.com)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Oct-30-25 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 10:00AM	uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 08:16AM	Breakout Momentum Plays You Need to Know About (MarketBeat)
Oct-22-25 04:58PM	uniQure N.V. (QURE): A Bull Case Theory (Insider Monkey) -5.01%
Oct-19-25 03:09AM	H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating (Insider Monkey)
Oct-13-25 05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-08-25 05:34AM	Jim Cramer on uniQure: "This One Has Too Many Questions for Me Up Here" (Insider Monkey)
Oct-03-25 04:14PM	QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop (MarketBeat)
Sep-30-25 12:46PM	uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission (Insider Monkey)
Sep-29-25 06:28PM	uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment (Insider Monkey) +9.37%

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

CEO & Executive DirectorMr. Matthew Craig Kapusta CPA

CFOMr. Christian Klemt

Ph.D.Dr. Jeannette Potts J.D.

Chief Medical OfficerDr. Walid Abi-Saab M.D.

Chairman of Scientific Advisory Board and Managing Director of UniQure-GermanyProf. Hugo Katus

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Option Exercise	19.39	21,082	408,780	540,309	Jul 07 04:47 PM
Kapusta Matthew C	CEO, Managing Director	Jul 02 '26	Sale	45.16	21,082	952,051	519,227	Jul 07 04:47 PM
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Option Exercise	5.59	10,000	55,900	178,235	Jul 02 04:59 PM
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Sale	46.42	30,000	1,392,600	148,235	Jul 02 04:59 PM
Kaye Jack	Director	Jun 30 '26	Option Exercise	23.44	21,167	496,230	43,056	Jul 02 04:54 PM
Kaye Jack	Director	Jun 30 '26	Sale	46.44	21,167	983,030	25,996	Jul 02 04:54 PM
Kapusta Matthew C	Officer	Jul 02 '26	Proposed Sale	45.15	21,082	951,932		Jul 02 04:00 PM
Abi-Saab Walid	Chief Medical Officer	Jun 26 '26	Sale	46.86	1,434	67,197	168,235	Jun 30 05:06 PM
Abi-Saab Walid	Chief Medical Officer	Jun 30 '26	Proposed Sale	46.42	30,000	1,392,643		Jun 30 04:01 PM
Kaye Jack	Director	Jun 30 '26	Proposed Sale	46.44	21,167	983,033		Jun 30 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Jun 25 '26	Option Exercise	31.71	28,716	910,584	547,943	Jun 26 05:15 PM
Kapusta Matthew C	CEO, Managing Director	Jun 24 '26	Option Exercise	31.71	4,128	130,899	525,923	Jun 26 05:15 PM
Kapusta Matthew C	CEO, Managing Director	Jun 25 '26	Sale	50.02	28,716	1,436,374	519,227	Jun 26 05:15 PM
Kapusta Matthew C	CEO, Managing Director	Jun 24 '26	Sale	50.00	6,696	334,800	519,227	Jun 26 05:15 PM
Abi-Saab Walid	Chief Medical Officer	Jun 26 '26	Proposed Sale	46.86	1,434	67,197		Jun 26 04:06 PM
Kapusta Matthew C	Officer	Jun 25 '26	Proposed Sale	50.02	28,716	1,436,305		Jun 25 04:00 PM
Kapusta Matthew C	Officer	Jun 24 '26	Proposed Sale	50.00	6,696	334,800		Jun 24 04:01 PM
Kapusta Matthew C	CEO, Managing Director	Jun 17 '26	Option Exercise	19.39	62,581	1,213,446	723,239	Jun 22 08:31 AM
Kapusta Matthew C	CEO, Managing Director	Jun 18 '26	Option Exercise	31.71	4,656	147,642	563,466	Jun 22 08:31 AM
Kapusta Matthew C	CEO, Managing Director	Jun 17 '26	Sale	44.32	164,429	7,288,062	558,810	Jun 22 08:31 AM
Kapusta Matthew C	CEO, Managing Director	Jun 18 '26	Sale	50.00	41,671	2,083,550	521,795	Jun 22 08:31 AM
Balachandran Madhavan	Director	Jun 17 '26	Option Exercise	24.97	11,685	291,807	54,939	Jun 22 08:05 AM
Balachandran Madhavan	Director	Jun 17 '26	Sale	45.06	11,685	526,485	43,254	Jun 22 08:05 AM
Kaye Jack	Director	Jun 17 '26	Option Exercise	31.71	5,295	167,904	31,291	Jun 22 07:54 AM
Kaye Jack	Director	Jun 17 '26	Sale	42.57	5,295	225,408	25,996	Jun 22 07:54 AM
Kapusta Matthew C	Officer	Jun 18 '26	Proposed Sale	46.38	41,671	1,932,516		Jun 18 05:57 PM
Kapusta Matthew C	Officer	Jun 17 '26	Proposed Sale	43.00	164,429	7,070,447		Jun 17 08:07 PM
Balachandran Madhavan	Director	Jun 15 '26	Option Exercise	8.49	10,000	84,900	53,254	Jun 17 05:02 PM
Balachandran Madhavan	Director	Jun 15 '26	Sale	27.85	10,000	278,500	43,254	Jun 17 05:02 PM
Potts Jeannette	Chief Legal Officer	Jun 15 '26	Sale	27.67	5,237	144,908	133,246	Jun 17 04:56 PM
Kaye Jack	Director	Jun 17 '26	Proposed Sale	42.57	5,295	225,393		Jun 17 04:34 PM
Balachandran Madhavan	Director	Jun 17 '26	Proposed Sale	45.05	11,685	526,463		Jun 17 04:03 PM
Potts Jeannette	Officer	Jun 15 '26	Proposed Sale	27.67	5,237	144,886		Jun 15 04:00 PM
Meek David D.	Director	Jun 11 '26	Sale	27.06	1,993	53,931	39,747	Jun 12 06:13 PM
Gut Robert	Director	Jun 10 '26	Option Exercise	16.04	2,645	42,426	34,987	Jun 12 06:04 PM
Gut Robert	Director	Jun 10 '26	Sale	26.05	7,552	196,720	27,435	Jun 12 06:04 PM
Gut Robert	Director	Jun 11 '26	Sale	27.06	2,726	73,766	32,259	Jun 12 06:04 PM
O'Keefe Kylie	Chief Customer & Strat Officer	Jun 11 '26	Sale	27.06	15,936	431,228	108,864	Jun 12 05:55 PM
Springhorn Jeremy P.	Director	Jun 11 '26	Sale	27.06	1,993	53,931	43,251	Jun 12 05:45 PM
POST LEONARD E	Director	Jun 11 '26	Sale	27.06	1,993	53,931	35,494	Jun 12 05:38 PM
Kaye Jack	Director	Jun 11 '26	Sale	27.06	1,993	53,931	25,996	Jun 12 05:30 PM
Jacques Rachelle Suzanne	Director	Jun 11 '26	Sale	27.06	1,993	53,931	33,903	Jun 12 05:15 PM
Balachandran Madhavan	Director	Jun 11 '26	Sale	27.06	1,993	53,931	43,254	Jun 12 05:08 PM
O'Keefe Kylie	Officer	Jun 11 '26	Proposed Sale	27.06	15,936	431,290		Jun 11 04:39 PM
Balachandran Madhavan	Director	Jun 11 '26	Proposed Sale	27.06	11,993	324,578		Jun 11 04:29 PM
Gut Robert	Director	Jun 11 '26	Proposed Sale	27.06	2,726	73,776		Jun 11 04:25 PM
Springhorn Jeremy P.	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:23 PM
Jacques Rachelle Suzanne	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:22 PM
POST LEONARD E	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:20 PM
Meek David D.	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:19 PM
Kaye Jack	Director	Jun 11 '26	Proposed Sale	27.06	1,993	53,938		Jun 11 04:18 PM
Gut Robert	Director	Jun 10 '26	Proposed Sale	26.05	7,552	196,725		Jun 10 04:00 PM
Kaye Jack	Director	Jun 03 '26	Option Exercise	16.04	2,645	42,426	23,084	Jun 05 04:43 PM
Kaye Jack	Director	Jun 03 '26	Sale	30.01	2,645	79,376	20,439	Jun 05 04:43 PM
Kaye Jack	Director	Jun 03 '26	Proposed Sale	30.01	2,645	79,384		Jun 03 03:58 PM
Abi-Saab Walid	Chief Medical Officer	May 08 '26	Option Exercise	5.59	25,000	139,750	214,669	May 12 04:54 PM
Abi-Saab Walid	Chief Medical Officer	May 08 '26	Sale	25.06	45,000	1,127,500	169,669	May 12 04:54 PM
Abi-Saab Walid	Chief Medical Officer	May 08 '26	Proposed Sale	25.05	45,000	1,127,435		May 08 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Mar 04 '26	Sale	9.06	14,581	132,104	660,658	Mar 06 05:07 PM
Abi-Saab Walid	Chief Medical Officer	Mar 04 '26	Sale	9.06	808	7,320	189,669	Mar 06 04:59 PM
Potts Jeannette	Chief Legal Officer	Mar 04 '26	Sale	9.06	3,412	30,913	138,483	Mar 06 04:35 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 04 '26	Sale	9.06	12,000	108,720	226,581	Mar 06 04:30 PM
Potts Jeannette	Officer	Mar 04 '26	Proposed Sale	9.06	3,412	30,927		Mar 04 04:56 PM
KLEMT CHRISTIAN	Officer	Mar 04 '26	Proposed Sale	9.06	12,000	108,770		Mar 04 04:50 PM
Kapusta Matthew C	Director	Mar 04 '26	Proposed Sale	9.06	14,581	132,165		Mar 04 04:46 PM
Kapusta Matthew C	CEO, Managing Director	Mar 02 '26	Sale	9.95	34,437	342,648	604,639	Mar 04 04:42 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 02 '26	Sale	9.95	12,532	124,693	198,981	Mar 04 04:36 PM
Potts Jeannette	Chief Legal Officer	Mar 02 '26	Sale	9.95	8,578	85,351	106,495	Mar 04 04:31 PM
Abi-Saab Walid	Chief Medical Officer	Mar 02 '26	Sale	9.95	1,660	16,517	148,777	Mar 04 04:25 PM
Kapusta Matthew C	Director	Mar 02 '26	Proposed Sale	9.95	34,437	342,586		Mar 02 05:39 PM
KLEMT CHRISTIAN	Officer	Mar 02 '26	Proposed Sale	9.95	12,832	127,655		Mar 02 05:29 PM
Potts Jeannette	Officer	Mar 02 '26	Proposed Sale	9.95	8,578	85,336		Mar 02 05:23 PM
Kapusta Matthew C	CEO, Managing Director	Feb 25 '26	Sale	23.86	12,378	295,339	639,076	Feb 27 04:49 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 25 '26	Sale	23.86	6,217	148,338	211,513	Feb 27 04:42 PM
Kapusta Matthew C	Director	Feb 25 '26	Proposed Sale	23.86	12,378	295,307		Feb 25 04:07 PM
KLEMT CHRISTIAN	Officer	Feb 25 '26	Proposed Sale	23.86	6,217	148,321		Feb 25 04:01 PM
Gut Robert	Director	Jan 12 '26	Option Exercise	14.08	17,810	250,765	57,955	Jan 14 04:26 PM
Gut Robert	Director	Jan 12 '26	Sale	24.62	25,613	630,483	32,342	Jan 14 04:26 PM
Kaye Jack	Director	Jan 09 '26	Option Exercise	19.39	6,390	123,902	26,829	Jan 12 04:21 PM
Kaye Jack	Director	Jan 09 '26	Sale	27.28	6,390	174,319	20,439	Jan 12 04:21 PM
Gut Robert	Director	Jan 12 '26	Proposed Sale	26.42	25,613	676,695		Jan 12 03:59 PM
Kaye Jack	Director	Jan 09 '26	Proposed Sale	27.28	6,390	174,330		Jan 09 03:59 PM
Gut Robert	Director	Nov 06 '25	Option Exercise	4.57	15,840	72,389	71,579	Nov 10 04:54 PM
Gut Robert	Director	Nov 06 '25	Sale	27.26	31,434	856,881	40,145	Nov 10 04:54 PM
Kaye Jack	Director	Nov 04 '25	Option Exercise	9.88	38,810	383,535	38,249	Nov 06 05:01 PM
Kaye Jack	Director	Nov 04 '25	Sale	30.34	38,810	1,177,517	20,439	Nov 06 05:01 PM
Gut Robert	Director	Nov 06 '25	Proposed Sale	26.06	31,434	819,170		Nov 06 04:13 PM
Kaye Jack	Director	Nov 04 '25	Proposed Sale	34.29	38,810	1,330,794		Nov 04 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Option Exercise	6.52	226,316	1,474,909	877,770	Sep 26 07:43 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Sale	41.46	226,316	9,382,473	651,454	Sep 26 07:43 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Option Exercise	5.37	15,000	80,550	232,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Option Exercise	13.03	3,000	39,090	220,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Sale	55.00	15,000	825,000	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Sale	40.04	3,000	120,120	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Officer	Sep 26 '25	Proposed Sale	55.00	15,000	825,000		Sep 26 04:04 PM
KLEMT CHRISTIAN	Officer	Sep 24 '25	Proposed Sale	40.00	3,000	120,000		Sep 24 08:01 PM
Kapusta Matthew C	Director	Sep 24 '25	Proposed Sale	41.45	226,316	9,381,750		Sep 24 07:59 PM

STVN

Stevanato Group Spa

QURE

uniQure NV

Upgrade your Finviz experience